Patents-Review.com
🔗 Permalink
Assignee profile:

Rottapharm Biotech S.R.L.

City:

Monza

Country:

Italy

Published Applications:

15

Last publication date:

2023-04-27

Patent Grants:

15

Last grant date:

2025-09-02

Top Inventors for applications by Rottapharm Biotech S.R.L.

These are the the leading inventors for applications assigned to Rottapharm Biotech S.R.L.:

Recent patent applications by Rottapharm Biotech S.R.L.

Rottapharm Biotech S.R.L. based in Monza, IT has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2023-04-27 ✅ Patent 12,404,245 granted on 2025-09-02
US20230127805A1
Chemistry; metallurgy

PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF

 #2 | 2023-04-20 ✅ Patent 12,544,365 granted on 2026-02-10
US20230122048A1
Human necessities

PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS

 #3 | 2023-03-02 ✅ Patent 12,509,446 granted on 2025-12-30
US20230061118A1
Chemistry; metallurgy

NEW FYN AND VEGFR2 KINASE INHIBITORS

 #4 | 2023-01-26 ✅ Patent 12,433,875 granted on 2025-10-07
US20230028519A1
Human necessities

(R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5] OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION

 #5 | 2022-05-12 ✅ Patent 11,590,114 granted on 2023-02-28
US20220142996A1
Human necessities

Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours

 #6 | 2021-05-06 ✅ Patent 11,718,582 granted on 2023-08-08
US20210130290A1
Chemistry; metallurgy

(R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist

 #7 | 2018-04-26 ✅ Patent 10,125,121 granted on 2018-11-13
US20180111919A1
Chemistry; metallurgy

FYN kinase inhibitors

 #8 | 2016-02-18 ✅ Patent 9,498,478 granted on 2016-11-22
US20160045500A1
Human necessities

Spiro aminic compounds with NK1 antagonist activity

 #9 | 2015-03-26 ✅ Patent 9,181,279 granted on 2015-11-10
US20150087626A1
Chemistry; metallurgy

Cyclic amine derivatives as EPreceptor antagonists

 #10 | 2015-03-05 ✅ Patent 9,174,977 granted on 2015-11-03
US20150065523A1
Chemistry; metallurgy

2-azabicyclo[4.1.0]heptane derivatives as orexin receptor antagonists for the treatment of certain disorders

 #11 | 2014-12-04 ✅ Patent 9,062,033 granted on 2015-06-23
US20140357653A1
Chemistry; metallurgy

Chemical compounds

 #12 | 2014-08-28 ✅ Patent 9,120,824 granted on 2015-09-01
US20140243373A1
Chemistry; metallurgy

Cyclic amine derivatives as EPreceptor agonists

 #13 | 2013-10-03 ✅ Patent 8,828,987 granted on 2014-09-09
US20130261100A1
Chemistry; metallurgy

Pyridine amide derivatives as EP4 receptor antagonists

 #14 | 2013-06-27 ✅ Patent 9,162,979 granted on 2015-10-20
US20130165494A1
Chemistry; metallurgy

1,5-Diary1-2-alkylpyrrole-3-substituted nitro esters, selective COX-2 inhibitors and nitric oxide donors

 #15 | 2012-05-10 ✅ Patent 8,859,608 granted on 2014-10-14
US20120115882A1
Chemistry; metallurgy

Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction

Also check out Rottapharm Biotech S.r.l.'s (Monza, Italy) applicant profile with 13 patent applications submitted.

AssigneeID:

134300 ⎘